key: cord-0874229-hdxjfafl
authors: Damanti, Sarah; Ramirez, Giuseppe Alvise; Bozzolo, Enrica Paola; Rovere‐Querini, Patrizia; De Lorenzo, Rebecca; Magnaghi, Cristiano; Scotti, Raffaella; Di Lucca, Giuseppe; Marinosci, Alessandro; Strada, Silvia; Di Terlizzi, Gaetano; Vitali, Giordano; Martinenghi, Sabina; Compagnone, Nicola; Landoni, Giovanni; Tresoldi, Moreno
title: 6‐Month Respiratory Outcomes and Exercise Capacity of COVID‐19 Acute Respiratory Failure Patients Treated With CPAP
date: 2021-05-07
journal: Intern Med J
DOI: 10.1111/imj.15345
sha: 86fe51a3135bd938925921d8c91a203193cf58f8
doc_id: 874229
cord_uid: hdxjfafl

BACKGROUND: COVID‐19 long‐term sequelae are ill‐defined since only few studies have explored the long‐term consequences of this disease so far. OBJECTIVE: to evaluate the 6‐month respiratory outcomes and exercise capacity of COVID‐19 acute respiratory failure (ARF) patients treated with continuous positive airway pressure (CPAP) during the first wave of the ongoing COVID‐19 pandemic. DESIGN: retrospective observational study. PATIENTS: COVID‐19 patients with ARF. INTERVENTIONS: CPAP during hospitalization and 6‐month follow‐up. MAIN MEASURES: frailty assessment through frailty index (FI), pO2/FiO2 during hospitalization and at follow‐up, respiratory parameters, 6‐min walking test (6MWT) and the modified British Medical Research Council (mMRC) and Borg scale at follow‐up. KEY RESULTS: more than half of the patients had no dyspnoea according to the mMRC scale. Lower in‐hospital pO2/FiO2 correlated with higher BORG scale levels after 6MWT (ρ 0.27; p 0.04) at follow up visit. FI was positively correlated with length of hospitalization (ρ 0.3; p 0.03) and negatively with the 6MWT walked distance (ρ ‐0.36; p 0.004). CONCLUSIONS: robust and frail patients with COVID‐19 ARF treated with NIV outside the intensive care unit setting had good respiratory parameters and exercise capacity at 6‐month follow‐up, although more severe patients had slightly poorer respiratory performance compared to patients with higher PaO2/FiO2 and lower FI. This article is protected by copyright. All rights reserved.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related disease is a systemic disease with prominent respiratory manifestations 1, 2 . Respiratory failure is relatively frequent in patients with COVID-19, implicating recurrent massive increases in the demand for hospitalisation and ventilation support for a wide number of subjects. Healthcare systems in most hit Countries have repeatedly proved unable to efficiently fulfil this demand, prompting to the identification of alternative treatments 1 . Continuous positive airway pressure (CPAP) ventilation, possibly in combination with respiratory physiotherapy has been found as an effective alternative to intubation in non-intensive care unit settings 3 . Little is known about the potential sequelae of COVID-19 4 , especially with regard to respiratory performance 5, 6 . In this observational study we evaluated the 6-month respiratory outcomes and exercise capacity of COVID-19 ARF patients treated with NIV during the first wave of the COVID-19 pandemic.

In this retrospective observational study we analysed the clinical status of patients attending a dedicated post-COVID-19 outpatient clinic 6±1 months after having been hospitalised with COVID-19 and acute respiratory distress syndrome in the Internal Medicine Departments of San Raffaele University Hospital, Milan, Italy.

Patients were included within the COVID-BioB protocol (NCT04318366) if they had been treated with CPAP without previous intubation. COVID-19 was diagnosed by the presence of signs and symptoms of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection in association with a positive reversetranscriptase polymerase chain reaction test from a nasal and/or throat swab and/or radiological findings consistent with COVID-19 pneumonia 7,8 . Patients with: i) chronically receiving CPAP for obstructive sleep apnoea; ii) previously intubated or requiring ICU during the same admission; iii) enrolled in a concomitant randomized trial on the use of early CPAP; iv) with severe contraindications to CPAP (e.g. coma or hemodynamic instability) were excluded 9 . After hospital discharge trained nurses organized follow-up appointments according to patients' discharge dates. In cases of missed follow-up appointments, patients were given the opportunity to reschedule the visits. Follow-up consultations were organized in the outpatient clinic of the Hospital and were performed 1, 3 and 6 months after discharge. In this study we analyzed the data collected during the 6-month follow-up visits.

Demographics, comorbidities, respiratory parameters including pO2/FiO2 ratio (calculated with the Rice equation from SpO2 when PaO2 was not available 10 were recorded on admission and after six months.

Radiographic Assessment of Lung Edema (RALE) scores were calculated on hospital admission, and scores≥ 9 considered indicative of severe lung involvement 11 . A 35-item frailty index (FI) was calculated according to the procedure described by Searle 12 using anamnestic data and baseline evaluation. FI scores above 0.25 were considered indicative of a frailty condition 12 . Follow-up data also encompassed the modified British Medical

Research Council (mMRC) dyspnoea scale 13 and a six-minute walking test (6MWT), including measurement of the Borg scale 14 before and after the test.

Descriptive statistics were used to analyze demographic data and long-term health consequences of COVID-19 patients. Spearman correlation was used to explore the association between clinical characteristics during hospital stay and comorbidities and 6-month outcomes. All statistical analyses were performed using SPSS (Statistical Package for the Social Sciences), version 26.0 (SPSS Inc. Chicago, IL, USA). Data are expressed as median (interquartile range) unless otherwise specified

Of 108/159 patients having been discharged, one died, 11 refused to attend to outpatient visits, one was unable to attend the visit and 28 were lost to follow up ( Figure 1 ). Table 1 illustrates the main characteristics of the sample who was followed-up. The majority (85%) of these patients were men and had a mean ± standard deviation age of 62.8 ± 10.77 years. Despite their relatively young age, 68% were frail (FI values >0.25).

However, just a minority of patients suffered from a chronic pulmonary pathology (Chronic Obstructive Pulmonary Disease 3%, asthma 3%, other chronic pulmonary diseases 3%). Patients who attended the visits and who were lost to follow-up did not differ in terms of demographics, clinical features and respiratory status during hospitalization.

At hospital admission the mean RALE score was 11.1 ± 6.72 and 39 patients (58.2%) had an elevated RALE score.

The 67.2% of the patients had a worst pO2/FiO2 during hospitalization < 100 (median 87.7, IQR 71.25 -100.75) CPAP tended to be administered for about half of the hospital stay. One patient manifested a minor CPAP complication (emesis).

No patient needed oxygen supply at 6-month follow-up. Oxygen saturation in room air and derived pO2/FiO2 were normal and so were the mean respiratory rate. Table 2 shows the respiratory and exercise parameters of the patients at the 6-month follow-up visits. Figure 2 illustrates the pO2/FiO2 trends for each patient. More than half of the sample had no dyspnoea according to the mMRC scale and the median predicted distance run across the 6MWT was 92% (IQR 84-99). Only four patients manifested strong or somewhat strong dyspnoea after the test.

Lower pO2/FiO2 correlated with higher BORG scale levels after 6MWT (ρ 0.27; p 0.04) at follow up visit.

Moreover, FI was positively correlated with length of hospitalization (ρ 0.3; p 0.03) and negatively with the 6MWT walked distance (ρ −0.36; p 0.004).

In this observational study we found that patients treated with CPAP for COVID-19 ARF, in spite of the severity of the SARS-CoV-2 infection, displayed good respiratory parameters and exercise capacity 6 months after hospital discharge. Patients who manifested a more severe disease had greater exertional dyspnoea at 6month follow-up. Frailer patients who had longer hospitalizations had the worst exercise capacity at followup.

Our results are consistent with those of Huang et al. who described a cohort of 1733 patients with COVID-19 and included 122 subjects treated with either high-flow nasal cannula, non-invasive or invasive ventilation. This subgroup had a median 85% completion of the predicted 6MWT distance after six months 6 . Patients with severe disease in the cohort by Huang et al. tended to be younger (median age 56 years compared to 63 years in our cohort), with a higher representation of women (36% vs 15% in our study) and with lower prevalence of hypertension (37% vs 44%) and diabetes (12% vs 28%). However, they showed longer hospitalizations (median 35 days vs 21 in our cohort) 6 . This evidence might suggest that prolonged hospitalisation with potential accrual of complications such as acute sarcopenia, might have negatively counterbalanced favourable demographic and clinical variables and might have had a prognostic impact on middle-term recovery 15, 16 .

Consistent with this hypothesis, muscle weakness along with mood disorders were prominently detected by Huang et al. and other authors 6, 17 . Conversely to other studies [18] [19] [20] , our data do not support a clinically relevant role of potential fibrotic complications following COVID-19-related ARF, at least at a functional level. Indeed, previous evidence from SARS survivors suggests that reduced exercise capacity at both 3-and 6-month followup time 21, 22 was mostly sustained by Critical Illness Myopathy and Neuropathy 23, 24 . It has been also demonstrated that few days of bedrest can impair muscle quantity, strength and performance even in healthy subjects 25 , suggesting a fortiori that this phenomenon would be particularly relevant in older people 26,27 . During acute illnesses catabolic stimuli imbalance muscle homeostasis increasing muscle degradation 28 . In COVID-19 patients this process could be particularly pronounced 29 due to the cytokine storm induced by the virus and to the iatrogenic hypercortisolaemia 30. Therefore COVID-19 patients are particularly at risk of developing acute sarcopenia. This acute organ insufficiency augments patients' vulnerability to stressors (i.e. it induces frailty) 31,32 and can aggravate a pre-existent frailty condition 33 , thus predisposing to negative clinical outcomes. Our study has the merit of having highlighted that robust and frail patients with COVID-19 ARF treated with CPAP outside the ICU setting had good respiratory parameters and exercise capacity at 6-month follow-up, even those receiving CPAP as the ceiling of treatment. CPAP has the advantage of allowing the treatment of a wider range of patients compared to invasive mechanical ventilation (IMV) and probably reduces the length of hospitalization compared to IMV. Moreover, CPAP avoids barotrauma and other negative consequences of IMV 37,38 . Some limitations of this study are worth to be mentioned. Our study did not encompass systematic spirometry and other pulmonary function tests, which constitutes a limitation to a comprehensive assessment of the course of respiratory recovery after COVID-19. Due to the high number of COVID-19 patients and the limited availability of the machinery for spirometry and diffusion lung carbon monoxide test, we decided to perform these tests as secondary level exams just in case of alterations at the clinical evaluation or at the walking test.

In a similar way, the lack of information about the degree of baseline dyspnoea and exercise capacity in these patients prevents further considerations about the impact of COVID-19 on pre-morbid respiratory status.

Finally, given the observational and monocentric design of the study, the role of CPAP on outcomes remains uncertain and further multicenter randomized studies should be performed to generalize these findings to other contexts.

In conclusion, by describing a relatively large cohort of homogeneous patients surviving severe COVID-19 after treatment with CPAP, we provide additional evidence supporting its use and novel clues about the natural history of COVID-19 after the acute phase. Our results also suggest that multidisciplinary assessment of respiratory and nutritional function of patients with severe COVID-19 both during hospitalization and during post-discharge follow-up might improve patient prognosis and quality of life. Accepted Article (1) 0 (0%) Weak dyspnea (2) 0 (0%) Moderate dyspnea (3) 0 (0%) Somewhat strong dyspnea (4) 0 (0%) Strong dyspnea (5) 1 (2%) Strong dyspnea (6) 0 (0%) Very strong dyspnea (7) 0 (0%) Very strong dyspnea (8) 0 (0%) Almost maximal (9) 0 (0%) Maximal dyspnea (10) 0 (0%) BORG scale after 6 minutes walking test** No dyspnea (0) 37 (55%) Extremely weak dyspnea (0.5) 10 (15%) Very weak dyspnea (1) 4 (6%) Weak dyspnea (2) 5 (8%) Moderate dyspnea (3) 1 (2%) Somewhat strong dyspnea (4) 3 (4%) Strong dyspnea (5) 1 (2%) Strong dyspnea (6) 1 (2%) Very strong dyspnea (7) 0 (0%) Very strong dyspnea (8) 0 (0%) Almost maximal (9) 0 (0%) Maximal dyspnea (10) 0 (0%) mMRC score 

Clinical Characteristics of Coronavirus Disease 2019 in China

Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis

Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in

Continuous positive airway pressure and pronation outside the intensive care unit in COVID 19 ARDS

Post-COVID-19 follow-up clinic: depicting chronicity of a new disease

6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

Design, validation, and clinical practice of standardized imaging diagnostic report for COVID-19

CT differential diagnosis of COVID-19 and non-COVID-19 in symptomatic suspects: a practical scoring method

British Thoracic Society Standards of Care C. Non-invasive ventilation in acute respiratory failure

Comparison of the SpO2/FIO2 ratio and the PaO2/FIO2 ratio in patients with acute lung injury or ARDS

Initial chest radiographs and artificial intelligence (AI) predict clinical outcomes in COVID-19 patients: analysis of 697 Italian patients

A standard procedure for creating a frailty index

Evaluation of clinical methods for rating dyspnea

Reproducibility of Borg scale measurements of dyspnea during exercise in patients with COPD

Frailty and sarcopenia: The potential role of an aged immune system

Acute Sarcopenia Secondary to Hospitalisation -An Emerging Condition Affecting Older Adults

Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic

Post-ARDS pulmonary fibrosis in patients with H1N1 pneumonia: role of follow-up CTRadiol med

Quality of life, pulmonary function, and tomographic scan abnormalities after ARDS

One-year outcomes in survivors of the acute respiratory distress syndrome

Pulmonary function and exercise capacity in survivors of severe acute respiratory syndrome

Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors

Long-Term outcomes after critical illness

Critical illness myopathy after COVID-19